Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Constellation) CPI-0610-02 / MANIFEST studyA Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)Leber, Dr BrianOpen to recruitmentNCT02158858
(CCTG) LY.17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaFraser, Dr GraemeRecruitment on hold - COVID-19NCT02436707
(Celgene) ACE-536-MDS-002 / COMMANDSA Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell TransfusionsLeber, Dr BrianRecruitment on hold - COVID-19NCT03682536
(Pfizer) B1761031A Single Arm, Open-label, Phase 4 Study Evaluating Qt Interval, Pharmacokinetics, And Safety Of Gemtuzumab Ozogamicin (Mylotarg (Trademarker)) As A Single-agent Regimen In Patients With Relapsed Or Refractory Cd33-positive Acute Myeloid LeukemiaLeber, Dr BrianRecruitment on hold - COVID-19NCT03727750
(UHN) CFI-400945-CL-002An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeLeber, Dr BrianRecruitment on hold - COVID-19NCT03187288
(UHN) SMART-AML-001Feasibility and validation study of the LSC17 score in acute myeloid leukemia (AML) patientsLeber, Dr BrianRecruitment on hold - COVID-19
Download PDF